Biovica International AB

Equities

BIOVIC B

SE0008613731

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:38 2024-04-26 am EDT 5-day change 1st Jan Change
1.706 SEK +6.36% Intraday chart for Biovica International AB -22.81% -33.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. CI
Biovica International AB Announces Divitum® Tka in Observational Trial CI
Biovica International AB Announces Appointments to the Nomination Committee CI
Transcript : Biovica International AB, Q3 2024 Earnings Call, Mar 14, 2024
Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University CI
Biovica International Signs SEK 1.2 Million Master Service Agreement CI
Biovica Signs Master Service Agreement for Tka Testing with Leading Pharma Company CI
Biovica Partners with Palex Group to Launch Breast Cancer Treatment Response Kits; Stock Surges MT
Biovica International Signs Agreement with Palex Group CI
Biovica Receives License for Maryland State CI
Transcript : Biovica International AB, Q2 2024 Earnings Call, Nov 28, 2023
Biovica International AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Biovica Receives Final Pricing Decision for DiviTum TKa Test by Medicare CI
Biovica Signs Commercial Partner Agreement for the Divitum(R) Tka Assay in the Nordics with Axlab CI
Biovica International AB Signs Agreement for DivTum(R) TKa with World Re-Known Cancer Clinic CI
Biovica Signs Second Agreement with US Healthcare Provider CI
Biovica Signs US Agreement with Leading Healthcare Provider in Arizona CI
Transcript : Biovica International AB, Q1 2024 Earnings Call, Sep 06, 2023
Biovica International AB Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Biovica Announces the Start of a DiviTum(R) TKa Clinical Trial CI
Biovica Lands US Commercial Deal for DiviTum TKa Blood Tests, Shares Jump 15% MT
Biovica Signs US Commercial Agreement with Occum Health CI
Biovica International Achieves PLA code for Medicare CI
Transcript : Biovica International AB, Q4 2023 Earnings Call, Jun 21, 2023
Chart Biovica International AB
More charts
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.706 SEK
Average target price
15 SEK
Spread / Average Target
+779.25%
Consensus
  1. Stock Market
  2. Equities
  3. BIOVIC B Stock
  4. News Biovica International AB
  5. Biovica Partners with Palex Group to Launch Breast Cancer Treatment Response Kits; Stock Surges